Friday, August 11, 2017 10:15 PM ET
Significant Insider purchase Extends the buy Trend of Last 90 Days in Shares of Eagle Pharmaceuticals (EGRX)
There was a noteworthy insider buying activity in Eagle Pharmaceuticals shares today as disclosed in a filing with the SEC. One insider — Douglas L Braunstein, Director — purchased 20,400 shares in the company having a net market value of approximately $1,001,087. There have been 2 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been buys resulting in the acquisition of 805 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net purchases of 21,205 shares and have averaged 7,068 shares per transaction over this time period.
Over the last 90 days, the number of insider buy/sell trades at Eagle Pharmaceuticals is greater than its 19-company peer group average. The Specialty & Advanced Pharmaceuticals peer group saw 37 buy/sell trades during this period for an average of 1.9 transactions per company. However, the number of shares traded per transaction by Eagle Pharmaceuticals insiders is lower than its peers. Within the peer group there were 282,854 shares purchased and 231,086 shares sold with company insiders purchasing 2,157 shares on average over this time period.
Insider buying and selling activity that is significant has been determined by eliminating all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers in creating and writing this story.
Using proprietary artificial intelligence methods, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at email@example.com. Copyright 2017 UpTick Data Technologies. All rights reserved.